Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ESG206 in systemic lupus erythematosus
CTR20262999Phase 2Active
- Sponsor
- Affinity Biopharma
- Start
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ESG206 in systemic lupus erythematosus (SLE), sponsored by Affinity Biopharma. Started Aug 2026; status: active.
02
Drugs
ESG206
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20262999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262999.